Loading
Latest filing published 03 Jun 2025 for X4 Pharmaceuticals, Inc, €2,288. Read the official filing
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Mark Baldry appears in our data through filings on X4 Pharmaceuticals, Inc shares, published by SEC (Form 4). In total, 8 filings cover trades dated from 31 October 2023 to 16 May 2025.
Market trades split into 2 purchases (€16k) and 2 sales (€13k). The net balance comes to €2,767 on the buying side. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. Other entries cover 4 share grants. In 2025 alone, the filings show 2 purchases and no sales.
Most recently, on 3 June 2025, the filings show a share grant worth €2,288 in X4 Pharmaceuticals, Inc. The clock since the last published purchase (20 May 2025) now reads 516 days. Typically, a trade is published a median of 4 days after it takes place. For comparison, the SEC allows two business days to file a Form 4. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
8 of 8 declarations